Back to Search Start Over

The endocannabinoid system and the molecular basis of paralitic ileus in mice

Authors :
Luisa Pinto
Anna Costagliola
Maria Grazia Cascio
Angelo A. Izzo
Nicola Mascolo
Vincenzo Di Marzo
A. Cecio
Francesco Capasso
Pasquale Maffia
Alessia Ligresti
Mascolo, NICOLA DOMENICO C. FERDINANDO
Izzo, ANGELO ANTONIO
Ligresti, A
Costagliola, Anna
Pinto, L
Cascio, M
Maffia, Pasquale
Cecio, A
Capasso, Raffaele
Di Marzo, V.
Izzo, Aa
Pinto, A
Cascio, Mg
Maffia, P
Capasso, Francesco
DI MARZO, V.
Source :
Scopus-Elsevier
Publication Year :
2002

Abstract

The endocannabinoid system (i.e., the cannabinoid receptors and their endogenous ligands) plays an important role in the physiological control of intestinal motility. However, its participation in intestinal pathological states is still poorly understood. In the present study, we investigated the possible role of the endocannabinoid system in the pathogenesis of paralytic ileus, a pathological state consisting of decreased intestinal motility following peritonitis, surgery, or other noxious situations. Ileus was induced by i.p. administration of acetic acid, and gastrointestinal propulsion was assessed by the charcoal method. Endocannabinoid levels were measured by isotope-dilution gas chromatography-mass spectrometry, whereas cannabinoid CB1 receptors were identified by immunohistochemistry. Acetic acid administration inhibited gastrointestinal transit (ileus), and this effect was accompanied by increased levels of the endocannabinoid anandamide compared with control mice and by overexpression of CB1 receptors in myenteric nerves. Furthermore, acetic acid-induced ileus was alleviated by the CB1 receptor antagonist SR141716A and worsened by VDM11, a selective inhibitor of anandamide cellular uptake (and hence inactivation). From these findings, it can be concluded that the intestinal hypomotility typical of paralytic ileus is due, at least in part, to the enhancement of anandamide levels and CB1 expression during this condition, and that selective, nonpsychotropic CB1 receptor antagonists could represent new drugs to treat this disorder.

Details

Language :
English
Database :
OpenAIRE
Journal :
Scopus-Elsevier
Accession number :
edsair.doi.dedup.....0d5a2b06f963607042bc1e9131291869